Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vomiting 3Nausea 3Delirium 2Recurrence 1Pain 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Radiotherapy 4Paclitaxel 4Carboplatin 4Sodium Chloride 3Oxaliplatin 3Cyclophosphamide 3Vincristine 2Surveys and Questionnaires 2Procarbazine 2Prednisolone 2Methotrexate 2Mental Status and Dementia Tests 2Magnetic Resonance Spectroscopy 2Magnesium Sulfate 2Leucovorin 2Duloxetine Hydrochloride 2Doxorubicin 2Dexamethasone 2Cytarabine 2Calcium Gluconate 2Amifostine 2Acupuncture Therapy 2neurotropin 1motexafin gadolinium 1haloperidol decanoate 1glutamic acid diethyl ester 1glucarpidase 1fludarabine phosphate 1fludarabine 1axicabtagene ciloleucel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neurotoxicity Syndromes × Lorazepam × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡